TrialCNS drugs2020

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.

Robert T Naismith et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.